BioSpace News Archive

Mainz Biomed N.V. announced it has entered into a Technology Rights Agreement with Socpra Sciences Santé Et Humaines S.E.C. to access a portfolio of novel mRNA biomarkers for potential future integration into ColoAlert, the Company’s highly efficacious, and easy-to-use detection test for colorectal cancer.

BioSpace, Inc., the leading life sciences news and careers site, has announced their selections for the industry’s most exciting up-and-coming companies in 2022.

Iktos and Astrogen announced that the companies have entered into a research collaboration agreement aimed at discovery of innovative small molecule pre-clinical drug candidates for Parkinson’s disease.

ITM Isotope Technologies Munich SE, a leading radiopharmaceutical biotech company, announced that CEO, Steffen Schuster will present a corporate overview and update at the virtual 40th Annual J.P. Morgan Healthcare Conference on Monday, January 10, 2022, at 8am ET.

IDEAYA Biosciences, Inc., a synthetic lethality focused precision medicine oncology company committed to the discovery and development of targeted therapeutics, reported the acquisition of its INQUIRE™ Chemical Library to enhance the company’s synthetic lethality drug discovery platform.

MannKind Corporation announced that its Chief Executive Officer Michael Castagna, PharmD, will present at the H.C. Wainwright Bioconnect Conference which will be available on demand starting on January 10, 2022.

Oculis S.A. announces the appointment of Mr. Webb Ding as global Chief Operating Officer and General Manager, China, with effect from February 1, 2022.

Amicus Therapeutics (Nasdaq: FOLD) today announced that management will present at the 40th Annual J.P. Morgan Healthcare Conference, being held virtually on Wednesday, January 12, 2022 at 3:45 p.m. E.T.

Renalytix plc (LSE: RENX) (NASDAQ: RNLX) (“Renalytix” or the “Company”) today announced the Company will be presenting at the upcoming 40th Annual J.P. Morgan Virtual Healthcare Conference.

MediPharm Labs Corp. a pharmaceutical company specialized in precision-based cannabinoids, is pleased to announce that it has completed all payments required under its 2020 $41 million unsecured convertible debt.